Paras Biopharmaceuticals Finland’s Post

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

Paras Biopharmaceuticals Finland Biologics has been actively involved in and has serviced campaigns in the USA and Europe over the last 10 years. We understand the challenges related to funding, time constraints, and quality. Paras Biopharmaceuticals, therefore, is carrying out this campaign on “Accelerated timelines for 2024 / 2025 batches for #Scale-up #Development & #Production.” We look forward to hearing about your projects and supporting the development of scale-up batches for your important ‘next steps,’ whether it’s Materials for Studies on IND Filing & Tox Materials. The quality of #Biologics will remain a priority even, with “accelerated timelines.” Affordable health, quality, and productivity are Paras Biopharmaceuticals’ contributions to your projects. #cdmo #biosimilars #technologies

Paras Biopharmaceuticals Finland Biologics has been actively involved in and has serviced campaigns in the USA and Europe over the last 10 years. We understand the challenges related to funding, time constraints, and quality. Paras Biopharmaceuticals, therefore, is carrying out this campaign on “Accelerated timelines for 2024 / 2025 batches for #Scale-up #Development & #Production.” We look forward to hearing about your projects and supporting the development of scale-up batches for your important ‘next steps,’ whether it’s Materials for Studies on IND Filing & Tox Materials. The quality of #Biologics will remain a priority even, with “accelerated timelines.” Affordable health, quality, and productivity are Paras Biopharmaceuticals’ contributions to your projects. #cdmo #biosimilars #technologies

𝗪𝗶𝘁𝗻𝗲𝘀𝘀 𝘁𝗵𝗲 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻: 𝗖𝗮𝗻 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗹𝗶𝗲𝗻𝘁𝘀 𝗧𝗿𝘂𝗹𝘆 𝗔𝗹𝗶𝗴𝗻 𝗼𝗻 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀? Happening now at Biologics Contract Manufacturing Asia 2024! Industry experts are taking the stage to tackle one of the biggest challenges in biologics manufacturing—regulatory alignment. Moderated by RAVI GANAPATHY from Hilleman Laboratories, this panel features Scott M. Wheelwright, PhD (Biolnno Bioscience), Michael J Kim (Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics) ), and Lucas Chan (CellVec Pte Ltd), sharing powerful insights on: • Harmonizing regulatory interpretations between contract manufacturers and clients. • Overcoming regional regulatory differences and ensuring seamless compliance. • The vital role of transparent communication to meet evolving expectations. • How proactive strategies can identify and mitigate regulatory risks before they become issues. • Real-world collaborative solutions for managing unforeseen regulatory challenges. Get ready for an engaging and eye-opening discussion on how manufacturers and clients can truly see eye to eye! #Biologics2024 #RegulatoryChallenges #Biomanufacturing #IndustryInsights #Compliance #PartnershipSuccess #BiopharmaLeadership

Innovative drugs play a vital role in #medical progress. Today, China's #biopharma ecosystem has reached unprecedented levels of innovation, with major impacts on both academia and industry. The Asia Summit on Global Health #ASGH2024 has partnered with The Hong Kong Polytechnic University to organise a thematic session titled "How Innovative Drugs Impact China's Biopharmaceutical Industry Ecosystem." Representatives from leading #pharmaceutical companies will share insights, discuss their latest drug innovations, and analyse their impact. Secure your spot now: https://bit.ly/3wkDXgw More details: https://bit.ly/49eeHac

New resources are up! PhRMA recently posted a new analysis showing the biopharmaceutical industry's economic impact throughout the United States. We also updated our interactive map with new national and state-specific factsheets detailing the sector's positive impacts on local economies. The factsheets are derived from the analysis completed by TEConomy Partners and reflect 2022 national and state economic data (latest available). In total, 47 states are involved in manufacturing FDA-approved medicines, and the industry contributes $1.7 trillion and supports nearly five million total American jobs.

The global CDMO market is projected to reach USD 530.3 billion by 2033, growing at a 7.7% CAGR, says Dimension Market Research. 💹 High in-house manufacturing costs and rising demand for biologics are key drivers. API manufacturing is expected to hold a 43.7% market share by end of 2024. These trends highlight significant investment and innovation opportunities, especially for Life Sciences professionals in the US, UK and Europe. 🌍 #CDMO #Pharmaceuticals #LifeSciences #MarketGrowth

The global CDMO market is projected to reach USD 530.3 billion by 2033, growing at a 7.7% CAGR, says Dimension Market Research. 💹 High in-house manufacturing costs and rising demand for biologics are key drivers. API manufacturing is expected to hold a 43.7% market share by end of 2024. These trends highlight significant investment and innovation opportunities, especially for Life Sciences professionals in the US, UK and Europe. 🌍 #CDMO #Pharmaceuticals #LifeSciences #MarketGrowth